Industries > Pharma > Global Asthma & COPD Therapies Market 2019-2029

Global Asthma & COPD Therapies Market 2019-2029

Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs

PUBLISHED: 19 March 2019
PAGES: 309
PRODUCT CODE: PHA0359
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD FREE SAMPLE

The global asthma & COPD therapies market was valued at $32bn in 2018 and is projected to grow at a CAGR of 6.0% in the first half of the forecast period. In 2018, the combination drugs segment held 39% of the global asthma & COPD market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 309-page report you will receive 112 tables and 131 figures– all unavailable elsewhere.

The 309-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Asthma & COPD Therapies Market forecasts from 2019-2029, further broken down into:
Global Asthma Therapies Market forecasts
Global COPD Therapies Market forecasts

Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:
• Bronchodilators monotherapy
• Anti-inflammatory drugs
• Combination drugs

Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:
• Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex
• Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,
• Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris

Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:
• Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex
• Anti-leukotrienes: Singulair
• Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab

Revenue forecast for the Combination drugs market and the leading drugs:
• Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo

• This report provides individual revenue forecasts from 2019-2029 for these regional and national markets:
• The US
• Japan
• EU5: Germany, France, UK, Italy, Spain
• BRIC: Brazil, Russia, India, China
• Mexico
• Other Countries

Global Asthma & COPD Therapies Market 2019-2029

• This report discusses the leading companies in the global asthma & COPD therapies market:
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
• Roche
• Teva

• This report discusses drugs currently in clinical development for treating asthma and COPD.

• This report discusses the SWOT analysis as well as porter’s five forces analysis of the global asthma & COPD therapies market.

Visiongain’s study is intended for anyone requiring commercial analyses for the global asthma & COPD therapies market. You find data, trends and predictions.

Buy our report today Asthma & COPD Therapies Market Analysis : Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Asthma & COPD Therapies Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Asthma & COPD Therapies Market 2019-2029


Latest Pharma news

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

READ

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

READ

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

READ

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2022-2032

The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.

13 September 2022

READ